Johnson & Johnson (NYSE:JNJ) Sets New 1-Year High – Still a Buy?

Johnson & Johnson (NYSE:JNJ)’s stock price reached a new 52-week high during mid-day trading on Monday. The company traded as high as $282.33 and last traded at $282.5090, with a volume of 2,259,662 shares changing hands. The stock had previously closed at $276.22.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: ICOTYDE met its Phase 3 primary endpoint in psoriatic arthritis. In biologic-naïve patients, 58% achieved an ACR20 response at Week 16, versus 41% on placebo. The result supports the potential of J&J’s once-daily oral treatment and is a significant late-stage pipeline milestone. Article: Johnson & Johnson Showcases Positive Trial Data For Key Autoimmune Therapies
• Positive Sentiment: An investigational prostate-cancer combination showed promising early results. In a Phase 1 study, 11 of 15 patients had PSA reductions of at least 50%, and nearly half had reductions of at least 90%. The regimen’s reported safety and potential for outpatient dosing are encouraging, but results are preliminary as it advances toward Phase 3. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: Nipocalimab adds evidence in Sjögren’s disease. New Phase 2 patient-experience findings highlight relief of dry mouth as a symptom patients value, complementing previously reported results on saliva production. This may help inform the drug’s development, although the update is not a new late-stage efficacy result. Article: Johnson & Johnson announces new Phase 2 nipocalimab study data
• Neutral Sentiment: J&J led a $100 million financing round for a biotech developing psychedelic-inspired medicines for depression. The investment offers exposure to an emerging area but has no clear near-term earnings impact. Article: J&J Backs Psychedelic-Inspired Biotech in $100 Million Round
• Negative Sentiment: One report said ETFs were net sellers of JNJ shares, totaling $68.4 million on Nov. 5. This may signal near-term selling pressure, but a single day of fund flows does not establish a change in the company’s fundamentals. Article: ETFs Are Net Sellers of Johnson & Johnson

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Guggenheim restated a “buy” rating and set a $287.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 7th. Royal Bank Of Canada reduced their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 14th. Argus set a $300.00 target price on Johnson & Johnson in a report on Wednesday, July 29th. Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $275.92.

Johnson & Johnson Stock Up 2.2%

The firm’s 50-day moving average is $265.91 and its two-hundred day moving average is $248.30. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The stock has a market cap of $679.70 billion, a P/E ratio of 42.81, a PEG ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Several large investors have recently bought and sold shares of the business. Outlook Capital Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth $28,000. Matrix Trust Co grew its holdings in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after buying an additional 54 shares during the period. Navigoe LLC increased its position in shares of Johnson & Johnson by 60.4% in the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after buying an additional 55 shares in the last quarter. Montgomery Financial Services LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $43,000. Finally, Hanseatic Management Services Inc. acquired a new stake in Johnson & Johnson during the 3rd quarter worth $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.